Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

類似資料

• Phase I Study of Vincristine, Irinotecan, and (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial
  著者:: DuBois, Steven G., 等
  出版事項: (2012)
• Response, Survival and Toxicity after (131)I-MIBG Therapy for Neuroblastoma in Pre-Adolescents, Adolescents and Adults
  著者:: Polishchuk, Alexei L., 等
  出版事項: (2011)
• Different outcomes for relapsed vs. refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)
  著者:: Zhou, Margaret J., 等
  出版事項: (2015)
• Phase 1 Study of Vorinostat as a Radiation Sensitizer with (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
  著者:: DuBois, Steven G., 等
  出版事項: (2015)
• Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With (131)I-Metaiodobenzylguanidine (MIBG)
  著者:: Trieu, Megan, 等
  出版事項: (2015)